Galena Biopharma Announces a Change to Its Board of Directors
December 24 2015 - 7:05AM
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company
committed to the development and commercialization of targeted
oncology therapeutics that address major unmet medical needs, today
announced that Steven A. Kriegsman has decided to retire as a
Director of the Company when his current term expires the day prior
to the June 2016 Annual Meeting of Stockholders. Mr.
Kriegsman has served as a Class III Director since 2006 and was a
member and chairman of several committees during his tenure.
Galena will commence a search for his replacement.
Sanford J. Hillsberg, J.D., Chairman of the Board, stated,
“Steve’s vision led to the creation of Galena in 2006 and he has
played a very active role as a member of our Board of Directors
since then, providing important guidance to the Company on many
issues during that time. On behalf of all the members of the
Board, I would like to sincerely thank Steve for his decade of
service and wish him much success with all of his current and
future endeavors.”
“I also would like to express my gratitude to Steve for his
numerous contributions to the Company and his personal support over
the years,” added Mark W. Schwartz, Ph.D., President and Chief
Executive Officer.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed
to the development and commercialization of targeted oncology
therapeutics that address major unmet medical needs. Galena’s
development portfolio is focused primarily on addressing the
rapidly growing patient populations of cancer survivors by
harnessing the power of the immune system to prevent cancer
recurrence. The Company’s pipeline consists of multiple mid- to
late-stage clinical assets, including novel cancer immunotherapy
programs led by NeuVax™ (nelipepimut-S) and GALE-301. NeuVax
is currently in a pivotal, Phase 3 clinical trial in breast cancer
with several concurrent Phase 2 trials ongoing both as a single
agent and in combination with other therapies. GALE-301 is in a
Phase 2a clinical trial in ovarian and endometrial cancers and in a
Phase 1b given sequentially with GALE-302. For more
information, visit www.galenabiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to,
statements about the progress of the commercialization of our
commercial products and development of Galena’s product candidates,
patient enrollment in our clinical trials, as well as other
statements related to the progress and timing of our development
activities, present or future licensing, collaborative or financing
arrangements or that otherwise relate to future periods. These
forward-looking statements are subject to a number of risks,
uncertainties and assumptions, including those identified under
“Risk Factors” in Galena’s Annual Report on Form 10-K for the year
ended December 31, 2014 and most recent Quarterly Reports on Form
10-Q filed with the SEC. Actual results may differ materially from
those contemplated by these forward-looking statements. Galena does
not undertake to update any of these forward-looking statements to
reflect a change in its views or events or circumstances that occur
after the date of this press release.
NeuVax is a trademark of Galena Biopharma, Inc.
Contact:
Remy Bernarda
SVP, Investor Relations & Corporate Communications
(925) 498-7709
ir@galenabiopharma.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2023 to Apr 2024